ReviewBlood cancer journal2018
Pathogenesis of bone disease in multiple myeloma: from bench to bedside.
Review in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04364724 (Prospective Application of CTFEA for Monitoring Disease Progression in Active Multiple Myeloma), which is not on this map. Cited by 206 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Application of CTFEA for Monitoring Disease Progression in Active Multiple Myeloma
Who cites it
206 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Mass spectrometry-based proteomics and metabolomics in multiple myeloma: a systematic review of prognostic biomarkers and minimal residual disease monitoring.Frontiers in medicine · 2026Pooled it
- Recent advances in research on the association between paediatric hyperuricaemia and bone health.Frontiers in endocrinology · 2026Pooled it
- Efficacy, safety and economy of denosumab and zoledronic acid in the treatment of bone metastases of solid tumors and multiple myeloma: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Biological research on the occurrence and development of multiple myeloma and its treatment.Immunity, inflammation and disease · 2023Pooled it
- Trial
- Revision and complication rates after total joint arthroplasty in patients with monoclonal gammopathy of undetermined significance and multiple myeloma.International orthopaedics · 2026Article
- Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma.Nature communications · 2026Article
- Increased Risk of Infections and Mortality Following Fractures in Multiple Myeloma: A Nationwide Population-Based Retrospective Cohort Study.Health science reports · 2026Article
- Risk factors and clinical impact of bone pain in patients with multiple myeloma - A prospective interdisciplinary study.Journal of bone oncology · 2026Article
- Article
- N-Azacytidine Inhibits Myeloma Cell Growth While Preserving Multiple Myeloma Patient Derived-Bone Marrow Mesenchymal Stromal Cells Differentiation.Metabolites · 2026Article
- Review
- Multiplexed Imaging Reveals Immune-Metabolic Niches in Multiple Myeloma Linked to Progression and Bone Disease.Blood cancer discovery · 2026Article
- Comparative Molecular Insights and Computational Modeling of Multiple Myeloma and Osteosarcoma.International journal of molecular sciences · 2026Review
- Emerging roles of RNA mInternational journal of oncology · 2026Review
- comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders.Cell stem cell · 2026Article
- Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable Outcomes.Cancers · 2026Article
- Can Exercise Training Improve the Quality of Life and Physical Function in Multiple Myeloma Patients?: Discussing the Progression of the Training Stimulus.Sports (Basel, Switzerland) · 2026Article
- Integrated RNA-seq and RT-qPCR Workflow Identifies Non-IGH Fusion Transcripts as Individualized Molecular Markers for Monitoring Multiple Myeloma.Biomedicines · 2026Article
- Myeloma-derived exosomal circ_0002724 promotes osteoclastogenesis through a miR-4753-3p/IFIT1 and RANK axis in myeloma bone disease.Frontiers in oncology · 2026Article
146 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteolytic bone disease is the hallmark of multiple myeloma, which deteriorates the quality of life of myeloma patients, and it affects dramatically their morbidity and mortality. The basis of the pathogenesis of myeloma-related bone disease is the uncoupling of the bone-remodeling process. The interaction between myeloma cells and the bone microenvironment ultimately leads to the activation of osteoclasts and suppression of osteoblasts, resulting in bone loss. Several intracellular and intercellular signaling cascades, including RANK/RANKL/OPG, Notch, Wnt, and numerous chemokines and interleukins are implicated in this complex process. During the last years, osteocytes have emerged as key regulators of bone loss in myeloma through direct interactions with the myeloma cells. The myeloma-induced crosstalk among the molecular pathways establishes a positive feedback that sustains myeloma cell survival and continuous bone destruction, even when a plateau phase of the disease has been achieved. Targeted therapies, based on the better knowledge of the biology, constitute a promising approach in the management of myeloma-related bone disease and several novel agents are currently under investigation. Herein, we provide an insight into the underlying pathogenesis of bone disease and discuss possible directions for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.